Abeona buys EoE drug candidate APT-1011, raises $30 million as ZEVASKYN sales grow
The company added a Phase 3-ready eosinophilic esophagitis asset and priced a private placement while reporting rising ZEVASKYN treatment volume and a new Medicare payment designation.
SEC filing (3)